Frontiers in Pharmacology · Nov 16, 2026

Updated evidence for oral PCSK9 inhibitors: a drug-specific, GRADE-assessed systematic review and meta-analysis of phase 3 enlicitide trials

By Chenchula S, Ghanta SN, R P et al.

Introduction: Oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an emerging class of lipid-lowering therapies that may improve adherence and accessibility compared with injectable agents. Methods: We systematically searched PubMed, Scopus, and Embase from inception to March 2026 for randomized controlled trials evaluating oral PCSK9 inhibitors (enlicitide, NNC0385-0434, AZD0780) in adults with hypercholesterolaemia. The primary outcome was the percentage change in low-density lipoprotein cholesterol (LDL-C). Secondary outcomes included any adverse events, serious adverse events, and discontinuation due to adverse events. Pooled estimates were calculated using random-effects models. Heterogeneity was assessed with I2 statistics. Certainty of evidence was evaluated using the GRADE framework. Results: Five trials comprising 4,065 participants were included. Oral PCSK9 inhibitors significantly reduced LDL-C compared with placebo (mean difference −58.37%, 95% CI –59.99 to −56.75; I2 = 0%). In drug-specific subgroup analysis, enlicitide (phase 3) showed a reduction of −58.57% (95% CI –60.30 to −56.84; I2 = 0%), while other agents (phase 2) showed a reduction of −56.88% (95% CI –63.13 to −50.64; I2 = 39.7%). There were no significant differences between treatment and placebo for any adverse events (RR 0.99, 95% CI 0.97–1.02), serious adverse events (RR 0.94, 95% CI 0.63–1.40), or discontinuation due to adverse events (RR 1.05, 95% CI 0.88–1.25). Certainty of evidence was high for LDL-C reduction, any adverse events, and discontinuation due to adverse events, and moderate for serious adverse events. Discussion: Oral PCSK9 inhibitors provide substantial LDL-C reductions with a safety profile comparable to placebo. These agents represent a promising oral alternative to injectable PCSK9-targeted therapies, though long-term cardiovascular outcome trials are still needed.

doi.org/10.3389/fphar.2026.1904883Open accessInterventions

AgingResearch.News